|
Match
|
Document |
Document Title |
|
|
6319493 |
Treatment of neoplastic disease with interleukin-10
A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.
|
|
|
6319894 |
Complexes and combinations of fetuin with therapeutic agents
There is disclosed a complex and a combination of the glycosylated polypeptide fetuin and a therapeutically active small molecule compound having a net positive charge at physiological pH. The...
|
|
|
6319517 |
Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation
The present invention to relates to a pharmaceutical preparation comprising lyophilized liposomes encapsulating a biologically-active principle which is highly insoluble in water and stable over time.
|
|
|
6319895 |
Lactoferrin tablets
Lactoferrin tablets comprising as the active ingredients lactoferrin and lactulose and having a horizontal hardness of at least 4 kg and a vertical hardness of at least 3 kg; and lactoferrin...
|
|
|
6312680 |
Methods of treatment using cytokine synthesis inhibitory factor
Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines...
|
|
|
6309646 |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
A method is disclosed for producing a soluble conjugate vaccine, and preferably protein/polysaccharide conjugates. In this process, the polysaccharide is reacted with a reagent so as to provide a...
|
|
|
6309633 |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
The invention provides a drug-oligomer conjugate having the following general formula: ##STR1## wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently...
|
|
|
6310039 |
Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at...
|
|
|
6306824 |
Uses of lipopolysaccharide binding protein
Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.
|
|
|
6306823 |
Purified new epididymal forward motility protein and a process for isolation of the said epididymal forward motility protein useful as a fertility promoter/blocker
The subject invention relates to a new forward motility protein isolated from goat epididymal plasma and a process for the isolation of the said epididymal forward motility protein useful as a...
|
|
|
6306395 |
Fas antigen derivatives
This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is...
|
|
|
6306900 |
Enteric coated pharmaceutical compositions
This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
|
|
|
6303113 |
Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
The present invention concerns a process for the production of well-tolerated, preserved injection or infusion solutions containing human protein.
|
|
|
6303114 |
IL-12 enhancement of immune responses to T-independent antigens
The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e.g., mammalian, including human), comprising administering to the...
|
|
|
6303580 |
Cyclitol Containing carbohydrates from human tissue which regulate lipogenic activity
The present invention provides for an isolated A-type substance having a structure identical to an A-type substance obtained from human liver or placenta, which is a cyclical containing...
|
|
|
6303126 |
Treatment of fibrosis by HGF
The present invention relates to a method for treating fibrosis caused by excessive collagen deposition. The method involves administering Hepatocyte Growth Factors (HGFs). The HGFs accelerate the...
|
|
|
6303127 |
Treatment of disease states
The invention presents methods for the treatment of symptoms associated with diseases states including cardiomyopathy, Parkinson's Disease and degenerative liver disease including cirrhosis...
|
|
|
6299870 |
Mutant human interferons
A new class of polypeptides is disclosed, along with a method for identifying and producing such polypeptides, having the characteristic of being unique to diseased states, particularly tumors and...
|
|
|
6296844 |
Asialocytokines and treatment of liver disease
The invention features methods for treating liver disease (e.g., viral hepatitis) by administering an asialocytokine (e.g., asialointerferon). The invention also includes methods of targeting a...
|
|
|
6297028 |
IL-2R-associated polypeptide and DNA molecules coding therefor
The present invention relates to a polypeptide, p43, which is associated with the interleukin-2 receptor (IL-2R). It binds specifically to the β and γ subunits of IL-2R and is further capable of...
|
|
|
6294523 |
Extended type 1 chain glycosphingolipids as tumor-associated antigens
A variety of compounds are provided which are useful as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the...
|
|
|
6294517 |
Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
The present invention describes novel compositions and kits comprising alpha-adrenergic receptor antagonists and compounds that donate, transfer or release nitric oxide, elevate endogenous levels...
|
|
|
6294540 |
Carbocyclic nucleoside hemisulfate and its use in treating viral infections
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2
-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
|
|
|
6294164 |
Natural killer cell enhancing factor C
A human natural killer cell enhancing factor C and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are...
|
|
|
6290948 |
Method of treating sepsis and ARDS using chamohine beta-10
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
|
|
|
6290972 |
Method of augmenting a vaccine response by administering CD40 ligand
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
6287606 |
Methods of enhancing wound healing and tissue repair
Tissue and organ repair, healing and augmentation are enhanced by administering pharmaceutically acceptable group IIIa element-containing compounds in amounts sufficient to provide therapeutic...
|
|
|
6288028 |
BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy
The present invention discloses new pharmaceutical compositions useful for the treatment of various human and animal diseases. These pharmaceutical compositions contain one or more peptides.
|
|
|
6288031 |
Method for reducing extravasation of effector cells
The present invention is a method for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The method is particularly adapted to...
|
|
|
6284237 |
Methods of treatment using IL-6
IL-6 is produced via recombinant DNA techniques. The peptide is useful in the treatment of disorders characterized by deficiencies in hematopoietic cells and in combination with other...
|
|
|
6284236 |
Cytokine that induces apoptosis
A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with...
|
|
|
6281192 |
Mucin containing ophthalmic preparations
The present invention discloses the ophthalmic applications of mucin derived from mammalian milk or milk byproducts. This mucin has been found to be a MUC1 type mucin similar to the transmembrane...
|
|
|
6280975 |
IL-6 mutein and DNA encoding thereto
The present invention relates to a new IL-6 mutein, a DNA sequence coding for it, its use in therapy as well as a pharmaceutical composition comprising it. It is a potent IL-6 antagonist and can be...
|
|
|
6281191 |
Compositions and methods for treating hepatitis-C
New compositions and methods for treating patients suffering from hepatitis-C, AIDS, aberrant apoptosis which include N-acetyl-D-glucosaminyl(β-1-4)-N-Acetyl-muramyl-L-ananyl-D-
isoglutami ne...
|
|
|
6280729 |
Preparation of factor IX
A novel method of protecting blood coagulation factor IX from proteases during purification or storage is disclosed. High concentrations of one or more water soluble organic or inorganic salts are...
|
|
|
6277829 |
Process for preparing of aqueous formulation for opthalmic use
The present invention describes a process for the preparation of aqueous formulations containing azithromycin for ophthalmic use, as well any formulations obtained by this process and their topical...
|
|
|
6277812 |
Methods for inhibiting TGF-β activity
The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide...
|
|
|
6274568 |
Compounds for altering cell surface sialic acids and methods of use therefor
The present invention is based on the identification of compounds in the form of biosynthetic precursors which can be used to modulate neuronal growth, inhibit cellular entry by pathogens and...
|
|
|
6274135 |
Method of using IL-11 for inflammation associated with acute pancreatitis
Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced...
|
|
|
6274547 |
Methods comprising the use of human interleukin-11 receptor proteins
Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, inhibitors of binding of human IL-11 and its receptor...
|
|
|
6274550 |
Azaftig, a proteoglycan for monitoring cachexia and for control of obesity
A proteoglycan ("azaftig") with a molecular weight of approximately 24,000 Dalton has been isolated and partially characterized from the urine of cachectic cancer and non-cancer patients. Azaftig...
|
|
|
6270759 |
Method of using IL-11 for treating gingivitis
Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced...
|
|
|
6270766 |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody....
|
|
|
6271200 |
Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
A mixed liposome pharmaceutical composition with multilamellar vesicles is provided. The vesicles are comprised of a pharmaceutical agent, membrane-mimetic amphiphiles and various phospholipids. A...
|
|
|
6268337 |
Methods for treating vascular disorders using activated protein C
A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The...
|
|
|
6267968 |
MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
Pharmaceutical compositions containing Muramyl dipeptide derivatives and conjugates or Muramyl dipeptide derivatives and conjugates combined with nucleoside derivatives which induce hematopoietic...
|
|
|
6268336 |
Pharmaceutical composition for treatment of hepatic diseases
The present invention relates to a pharmaceutical composition for treatment of hepatic diseases which comprises erythropoietin as an active ingredient to reduce excess iron ions in the liver of a...
|
|
|
6264950 |
Product and process for T lymphocyte immunosuppression
The present invention relates to a product and process for suppressing an immune response using a T lymphocyte veto molecule capable of blocking cell surface molecules responsible for T cell...
|
|
|
6265374 |
Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
A method of treating inflammation in patients in need of such treatment by administering an effective amount of I-A-B-C-D-E-F-G-H-II (General Formula), wherein A is Ala, Gly, Val, Ser, Thr or...
|
|
|
6264951 |
Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|